FBRX logo

FORTE BIOSCIENCES INC

FBRXNASDAQ
πŸ† #2061 by market capUS Equity
$77.00β–² $0.04 (+0.05%)
Pre-market Β· at close
πŸ””
Track FBRX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.1%
7dβ€”
14dβ€”
30dβ€”
ytdβ–² 180.0%
1yβ–² 432.5%
🏦Market Cap
$1.63B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-99.8%
Declining
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
40860.7x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$76.97 – $77.00
52-Week Range
$10.30 – $77.20
Volume (shares)
57,036
Avg Volume (shares)
β€”
Shares Outstanding
21.2M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
40860.7x
EPS (TTM)
$-4.60
Dividend Yield
β€”
Dilution (1yr)
+179.4%
FBRX logo

FORTE BIOSCIENCES INC

FBRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$71Mβ–² +93.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$51Mβ–² +65.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
17.9Mβ–² +179.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$77Mβ–² +$55M YoY
StockOtter Β· stockotter.space

About FORTE BIOSCIENCES INC

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.